“人工智能+医药”产业现状和趋势

Current Situation and Trend of"Artificial Intelligence+Medicine"Industry

“人工智能(AI)+医药”产业是指将AI、机器学习等新兴技术应用到医药研发领域,用计算技术解读数据、刻画生命活动。“AI+医药”产业有望改变传统生化技术红利消退、新药研发成本持续走高的全球性困境。全球医药头部企业都已经在药物研发的各环节布局AI技术。我国生物医药产业正处在由仿制向创新迈进的关键爬坡期,供应端需要构建新技术驱动力。然而,想要真正实现“AI+医药”产业“大势所趋”的发展愿景,还存在一定的困难和问题,如数据权益分割、法律风险保障等。总之,“AI+医药”产业将成为中国未来重要的产业领域之一,但仅凭市场力量并不能使其流畅运行,衔接好各方利益,打造生态闭环是必要条件。

The AI+Pharmaceutical industry refers to the application of emerging technologies,such as Artificial Intelligence and Machine Learning,in pharmaceutical research and development,using computational techniques to interpret data and depict life activities.This industry is expected to change the global predicament of the dividend decline of traditional biochemical technology and continuously rising costs for new drug development.Global pharmaceutical giants have already laid out AI+technology at various stages of drug R&D.China's biopharmaceutical industry is currently transitioning from imitation to innovation,which requires new technology-driven forces on the supply side.However,the realization of the AI+Pharmaceutical industry vision also faces certain difficulties and issues,such as data equity division,legal risk protection,etc.In short,AI+Pharmaceutical industry will become one of China's important industries in the future.However,it cannot run smoothly by market forces alone.It is necessary to connect all parties'interests together and create an ecological closed loop.